How to Handle Dropouts and Protocol Deviations in Clinical Trial Analysis

Dropouts and protocol deviations are almost inevitable in clinical trials. Whether due to patient withdrawal, non-adherence, or procedural inconsistencies, these events can distort the trial results if not properly handled. Regulators like the USFDA and EMA expect clear definitions and pre-specified methods for managing these issues in both the protocol and Statistical Analysis Plan (SAP).

This tutorial explains how to classify, analyze, and report dropouts and protocol deviations in a way that preserves data integrity, ensures regulatory compliance, and supports valid conclusions from your clinical trial.

What Are Dropouts and Protocol Deviations?

Dropouts:

Subjects who discontinue participation before completing the study, often due to adverse events, lack of efficacy, consent withdrawal, or personal reasons.

Protocol Deviations:

Any departure from the approved trial protocol, whether intentional or unintentional, including incorrect dosing, visit window violations, or missing assessments.

Proper classification and documentation of both are required in GMP-compliant studies.

Types of Protocol Deviations

• Major Deviations: Affect the primary endpoint or trial integrity (e.g., incorrect randomization)
• Minor Deviations: Do not impact key trial outcomes (e.g., visit outside window)
• Eligibility Deviations: Inclusion of ineligible subjects
• Treatment Deviations: Non-adherence to investigational product protocol

Major deviations usually exclude subjects from the Per Protocol (PP) analysis set but may remain in the Intent-to-Treat (ITT) set.

Statistical Approaches for Dropouts

1. Intent-to-Treat (ITT) Analysis:

Includes all randomized subjects, regardless of adherence or dropout. This approach preserves randomization benefits and is the gold standard for efficacy trials.

However, missing data due to dropouts must be addressed using methods such as:

• Mixed Models for Repeated Measures (MMRM)
• Multiple Imputation (MI)
• Pattern-Mixture Models
• Last Observation Carried Forward (LOCF) – discouraged for primary analysis

2. Per Protocol (PP) Analysis:

Includes only subjects who adhered strictly to the protocol. This provides a clearer picture of treatment efficacy under ideal conditions.

It is often used as a supportive analysis to ITT and must be predefined in the SAP and CSR.

Handling Protocol Deviations in Analysis

Deviations should be categorized and analyzed for their impact. Best practices include:

• Pre-specify major vs minor deviations in the SAP
• Perform sensitivity analysis excluding subjects with major deviations
• Justify inclusion/exclusion of deviators in each analysis set
• Report all deviations in the CSR by type and frequency

Major deviations that affect endpoints (e.g., missing primary assessments) should typically exclude those subjects from PP analysis.

Estimand Framework and Intercurrent Events

The ICH E9(R1) guideline encourages defining “intercurrent events,” which include dropouts and deviations. These are addressed through different strategies like:

• Treatment Policy: Analyze all randomized subjects regardless of intercurrent events
• Hypothetical: Model the outcome as if the event had not occurred
• Composite: Combine event with outcome into a single endpoint
• Principal Stratum: Restrict analysis to subgroup unaffected by the event

Choosing the right estimand and handling approach is a regulatory expectation and should align with trial registration strategies.

Regulatory Expectations for Dropouts and Deviations

USFDA: Emphasizes transparency in dropout handling and discourages LOCF as a primary method. Requires dropout reasons to be detailed in submission.

EMA: Requires analysis of protocol adherence and impact on efficacy interpretation. Supports multiple sensitivity analyses.

CDSCO: Encourages sponsor accountability in tracking and preventing protocol violations. Dropout management is critical during audits.

Best Practices for Managing Dropouts and Deviations

• Include dropout prevention strategies in the protocol
• Use eCRFs to track deviation type, reason, and impact
• Train sites on protocol adherence and data quality
• Implement real-time deviation monitoring dashboards
• Review deviation reports during interim data reviews

Example Scenario

In a Phase III diabetes trial, 10% of patients dropped out before the Week 24 endpoint. ITT analysis used MMRM to handle missing data, assuming MAR. A per-protocol analysis excluded 6% with major protocol deviations. Sensitivity analyses using pattern-mixture models supported the robustness of findings, as treatment effect remained statistically significant under all assumptions. The FDA approved the submission based on the transparent and well-planned analysis of dropouts and deviations.

Conclusion

Handling dropouts and protocol deviations effectively is essential for the credibility and regulatory acceptance of your clinical trial. Start with proper planning and classification, follow with appropriate statistical handling, and ensure transparent documentation. Using robust ITT and PP analyses, backed by sensitivity analyses and regulatory guidance, helps ensure that your results are reliable, unbiased, and ready for global submission.

How to Adjust Sample Size for Dropouts and Noncompliance in Clinical Trials

One of the most overlooked yet critical steps in clinical trial planning is adjusting the calculated sample size to account for patient dropouts and noncompliance. These real-world challenges can significantly reduce the effective power of a study, increasing the risk of inconclusive or biased results. Proactively planning for attrition and protocol deviations ensures the integrity and regulatory acceptability of trial outcomes.

This guide walks through the rationale, formulas, and best practices for adjusting sample sizes for expected dropouts and noncompliance, aligned with expectations from regulatory authorities such as the USFDA and CDSCO.

Why Adjust for Dropouts and Noncompliance?

The ideal number of subjects calculated from a power analysis assumes perfect retention and compliance. However, in real trials:

• Participants may withdraw due to side effects, relocation, or personal reasons
• Subjects may not follow the protocol (miss doses, skip visits)
• Data may be incomplete or lost

These issues compromise the **intention-to-treat (ITT)** and **per-protocol (PP)** populations, reducing power and introducing bias. Adjusting for this anticipated loss ensures that the trial meets its original objectives.

Understanding Dropouts vs. Noncompliance

Dropouts

Participants who discontinue the study prematurely and do not provide complete endpoint data. This affects both ITT and PP analyses.

Noncompliance

Subjects who remain in the study but deviate from the treatment protocol. Their inclusion/exclusion may affect only PP analyses.

Step-by-Step: Adjusting the Sample Size

Step 1: Calculate Initial Sample Size

Use standard formulas based on effect size, alpha, power, and variability, assuming 100% compliance and no attrition.

Step 2: Estimate Dropout and Noncompliance Rates

Base your assumptions on:

• Previous trials in similar indications
• Pilot studies or feasibility assessments
• Therapy burden, follow-up duration, and patient population

Typical dropout rates:

• Short-duration trials: 5–10%
• Chronic conditions: 15–25%
• Oncology or long-term follow-up: ≥30%

Step 3: Inflate Sample Size

The adjusted sample size (n_adjusted) can be calculated using:

  nadjusted = n / (1 − d)
  

Where:

• n = Initial sample size per group
• d = Anticipated proportion of dropouts/noncompliant subjects (e.g., 0.15 for 15%)

Example:

Initial sample size = 120 subjects

Expected dropout = 20%

Adjusted sample size = 120 / (1 − 0.20) = 150 subjects

Handling Multiple Attrition Risks

In some studies, dropout and noncompliance are treated separately. A conservative approach is to add buffers sequentially:

  n′ = n / (1 − dropout) × (1 − noncompliance)
  

Example:

Dropout = 15%, Noncompliance = 10%

n′ = n / (0.85 × 0.90) = n / 0.765

→ Inflate by ~30.7%

Regulatory Perspective on Adjustments

Both regulatory agencies and ethics committees expect realistic planning for attrition. Key expectations:

• Justification of dropout and noncompliance estimates
• Impact assessment on statistical power and endpoint interpretation
• Clear documentation in the SAP and clinical protocol
• Plans for patient engagement and retention strategies

Best Practices for Managing Dropout Impact

1. Historical Data: Use dropout rates from comparable studies as a baseline
2. Protocol Design: Reduce patient burden to minimize attrition
3. Patient Engagement: Incorporate reminders, follow-ups, and retention campaigns
4. Monitoring: Track dropout trends throughout the study for early correction
5. Analysis Populations: Plan ITT, PP, and as-treated analysis sets in advance

Example in Practice: Phase 3 Diabetes Trial

• Initial calculated sample: 180 subjects per arm
• Expected dropout: 15%
• Expected noncompliance: 10%
• n_adjusted = 180 / (0.85 × 0.90) = 235 subjects

The team would plan to recruit 470 subjects total to ensure 360 compliant completers for final analysis.

Tools and Resources

• Sample size calculators with dropout adjustment modules (e.g., G*Power, nQuery)
• Statistical programming in R (e.g., pwr and epiDisplay packages)
• Validation of calculations through pharmaceutical validation processes

Common Mistakes to Avoid

• Using generic dropout rates without context
• Failing to document adjustments in SAP
• Over-recruiting without power recalculation
• Ignoring compliance monitoring plans
• Assuming retention efforts alone will suffice

Conclusion: Proactive Adjustment Ensures Trial Integrity

Failing to account for dropouts and noncompliance can jeopardize an otherwise sound clinical trial. Adjusting the sample size with realistic estimates helps maintain statistical power and aligns with ethical and regulatory expectations. This essential step should be incorporated early during the SAP and protocol development phases, ideally with involvement from a biostatistics and quality assurance team.

Explore More:

• Stability testing protocols
• Pharma SOP checklist
• GMP documentation